IRIS
MARTINELLI, Erika
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 3.507
NA - Nord America 3.016
AS - Asia 618
OC - Oceania 13
SA - Sud America 4
AF - Africa 3
Continente sconosciuto - Info sul continente non disponibili 2
Totale 7.163
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.980
IE - Irlanda 1.246
IT - Italia 579
GB - Regno Unito 374
UA - Ucraina 353
DE - Germania 322
FR - Francia 248
CN - Cina 227
SG - Singapore 187
SE - Svezia 107
GR - Grecia 104
FI - Finlandia 103
TR - Turchia 81
KR - Corea 58
CA - Canada 34
BE - Belgio 21
PK - Pakistan 20
VN - Vietnam 20
CZ - Repubblica Ceca 16
IN - India 12
NL - Olanda 8
AU - Australia 7
IR - Iran 6
NZ - Nuova Zelanda 6
AT - Austria 4
CH - Svizzera 4
ES - Italia 4
HK - Hong Kong 4
RU - Federazione Russa 4
MK - Macedonia 3
BR - Brasile 2
EU - Europa 2
GI - Gibilterra 2
MX - Messico 2
PL - Polonia 2
AR - Argentina 1
EG - Egitto 1
HU - Ungheria 1
JP - Giappone 1
LK - Sri Lanka 1
MA - Marocco 1
MY - Malesia 1
PE - Perù 1
RO - Romania 1
RS - Serbia 1
ZA - Sudafrica 1
Totale 7.163
Salva come PNG Salva come JPEG
Città #
Dublin 1.234
Chandler 613
Jacksonville 580
Princeton 171
Bremen 146
Roxbury 143
Medford 131
New York 127
Ann Arbor 106
Singapore 105
Wilmington 78
Caserta 75
Beijing 74
Naples 73
Boardman 54
Cambridge 46
Des Moines 43
Munich 42
San Mateo 41
Nanjing 37
Woodbridge 36
Seoul 35
Napoli 32
Los Angeles 29
Ashburn 26
Elora 22
Brussels 21
Dong Ket 20
Norwalk 20
Houston 18
Mountain View 17
Brno 14
Nanchang 13
Helsinki 12
Milan 11
Düsseldorf 10
Lappeenranta 10
Redwood City 10
Rome 10
Auburn Hills 9
Jinan 9
Tianjin 9
Bahawalpur 8
Cava Dei Tirreni 7
Pozzuoli 7
Shanghai 7
Florence 5
Guangzhou 5
Ottawa 5
Shenyang 5
Taiyuan 5
Taizhou 5
Venice 5
Battipaglia 4
Castellammare Di Stabia 4
Fairfield 4
Hangzhou 4
Hebei 4
Lanzhou 4
Monte Di Procida 4
Ningbo 4
Redmond 4
Sennori 4
Vienna 4
Zhengzhou 4
Zurich 4
Amsterdam 3
Changchun 3
Colle di Val d'Elsa 3
Ercolano 3
Groningen 3
Hanover 3
Kunming 3
Lodi 3
London 3
Madrid 3
Montecorvino Rovella 3
Mugnano Di Napoli 3
Mugnano di Napoli 3
Nola 3
Seregno 3
Toronto 3
Viareggio 3
Anantapur 2
Andover 2
Athens 2
Avellino 2
Benevento 2
Brdo 2
Caivano 2
Casoria 2
Central 2
Chicago 2
Cinquevie 2
Corbara 2
Forino 2
Giugliano in Campania 2
Hong Kong 2
Hyderabad 2
Jiaxing 2
Totale 4.513
Salva come PNG Salva come JPEG
Nome #
ONCOLOGIA MEDICA 145
EPHA2 is a predictive biomarker of resistance and a potential therapeutic target for improving anti-epidermal growth factor receptor therapy in colorectal cancer 100
Comparative study of NGS platform ion torrent personal genome machine and therascreen rotor-gene Q for the detection of somatic variants in cancer. 90
Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells 86
Primary and Acquired Resistance of Colorectal Cancer to Anti-EGFR Monoclonal Antibody Can Be Overcome by Combined Treatment of Regorafenib with Cetuximab. 85
Molecular aspects of resistance to biological and non-biological drugs and strategies to overcome resistance in colorectal cancer. 79
Clinical practice use of liquid biopsy to identify RAS/BRAF mutations in patients with metastatic colorectal cancer (mCRC): A single institution experience 79
Anti-epidermal growth factor receptor monoclonal antibodies in cancer therapy. 78
Elevated perioperative serum vascular endothelial growth factor levels in patients with colon carcinoma. 76
Antitumor efficacy of Kisspeptin in human malignant mesothelioma cells 75
A multicenter phase II study of induction chemotherapy with FOLFOX-4 and cetuximab followed by radiation and cetuximab in locally advanced oesophageal cancer 72
Antitumor activity of bortezomib in human cancer cells with acquired resistance to anti-epidermal growth factor receptor tyrosine kinase inhibitors 71
TRASTUZUMAB RESISTANCE IN BREAST CANCER 71
Primary and Acquired Resistance of Colorectal Cancer Cells to Anti-EGFR Antibodies Converge on MEK/ERK Pathway Activation and Can Be Overcome by Combined MEK/EGFR Inhibition. 68
Farmacogenomica e cancro colorettale 66
Adjuvant chemoradiotherapy in patients with stage III-IV radically resected gastric cancer: a pilot study 66
Antitumor activity of ZD6474, a vascular endothelial growth factor-2 and epidermal growth factor receptor small molecule tyrosine kinase inhibitor, in combination with SC-236, a cyclooxygenase-2 inhibitor 65
AXL is an oncotarget in human colorectal cancer 65
antitumor activity of zd6474, a VEGFR-2 and EGFR small molecule tyrosine kinase inhibitor in combination with SC-236, a cicloxigenase-2 inhibitor 65
Intrinsic resistance to selumetinib, a selective inhibitor of MEK1/2, by cAMP-dependent protein kinase A activation in human lung and colorectal cancer cells. 62
Chemoradiotherapy as adjuvant treatment of gastric cancer 60
A case report of a severe fluoropyrimidine-related toxicity due to an uncommon DPYD variant 60
Antitumor activity of dual blockade of PD-L1 and MEK in NSCLC patients derived three-dimensional spheroid cultures 60
Vascular endothelial growth factor and neo-angiogenesis in H. pylori gastritis in humans. 59
Antitumor activity of sorafenib in human cancer cell lines with acquired resistance to EGFR and VEGFR tyrosine kinase inhibitors. 59
Long-term Clinical Outcome of Trastuzumab and Lapatinib for HER2-positive Metastatic Colorectal Cancer 59
Comprehensive genome profiling by next generation sequencing of circulating tumor DNA in solid tumors: a single academic institution experience 59
Increased TGF-α as a mechanism of acquired resistance to the anti-EGFR inhibitor cetuximab through EGFR-MET interaction and activation of MET signaling in colon cancer cells 58
Combination of anti-EGFR drugs and other molecular targeted agents as anti-cancer strategy 58
Antitumour efficacy of MEK inhibitors in human lung cancer cells and their derivatives with acquired resistance to different tyrosine kinase inhibitors 58
Clinical outcome and molecular characterisation of chemorefractory metastatic colorectal cancer patients with long-term efficacy of regorafenib treatment 58
Synergistic Antitumor Activity of Sorafenib in Combination with Epidermal Growth Factor Receptor Inhibitors in Colorectal and Lung Cancer Cells 57
Interleukin-6 serum level correlates with survival in advanced gastrointestinal cancer patients but is not an independent prognostic indicator 57
Clinical activity of FOLFIRI plus cetuximab according to extended gene mutation status by next generation sequencing: findings from the CAPRI-GOIM trial. 55
Capecitabine plus weekly oxaliplatin in gastrointestinal tumors. A phase I study 55
Pegylated liposomal doxorubicin: pharmacologic and clinical evidence of potent antitumor activity with reduced anthracyclina-induced cardiotoxicity (review) 55
Post- operative xelox and chemoradiation in stage III-IV radically resected gastric cancer patients: preliminary results of a pilot study. 55
Complete response to preoperative chemoradiation and survival in esophageal cancer : a pooled analysis of three singe-institution phase II trials. 55
Clinical outcome of patients with chemorefractory metastatic colorectal cancer treated with trifluridine/tipiracil (TAS-102): a single Italian institution compassionate use programme 54
Clinical activity and tolerability of FOLFIRI and cetuximab in elderly patients with metastatic colorectal cancer in the CAPRI-GOIM first-line trial 54
Weekly docetaxel and capecitabine is not effective in the treatment of advanced gastric cancer: A phase II study 53
Targeted approach to metastatic colorectal cancer: what comes beyond epidermal growth factor receptor antibodies and bevacizumab? 53
Targeting EGFR in Pancreatic Cancer Treatment. 53
Epidermal growth factor receptor inhibitors in non-small-cell lung cancer. 52
Correlation between efficacy and skin rash occurrence following treatment with the epidermal growth factor receptor inhibitor cetuximab: a single institution retrospective analysis 51
Elevated serum levels of interleukin-8 in advanced non-small cell lung cancer patients: Relationship with prognosis 51
Tumori neuroendocrini (NETs) 51
MET ACTIVATION BY AUTOCRINE LOOP RESCUES COLON CANCER CELLS FROM SENSITIVITY TO EGFR INHIBITION 51
Activity and molecular targets of pioglitazone via blockade of proliferation, invasiveness and bioenergetics in human NSCLC 51
Optimizing treatment of metastatic colorectal cancer patients with anti-EGFR antibodies: overcoming the mechanisms of cancer cell resistance. 50
Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial. 50
Trifluridine/Tipiracil (TAS-102) in Refractory Metastatic Colorectal Cancer: A Multicenter Register in the Frame of the Italian Compassionate Use Program 50
Preoperative chemo-radiotherapy for carcinoma of the esophagus 49
Combination of epidermal growth factor receptor inhibitors and antiangiogenic drugs: a model for treatment 49
Erlotinib in cancer treatment 49
The new European gold standard treatment for rectum cancer 48
Interaction between the epidermal growth factor receptor (EGFR) and the vascular endothelial growth factor (VEGF) pathways: a rational approach for multi-target anticancer therapy 48
Sequential HER2 blockade as effective therapy in chemorefractory, HER2 gene-amplified, RAS wild-type, metastatic colorectal cancer: learning from a clinical case 48
It is finally time for adjuvant therapy in melanoma 48
Regorafenib in combination with silybin as a novel potential strategy for the treatment of metastatic colorectal cancer 48
Weekly chemotherapy with cisplatin and paclitaxel and concurrent radiation therapy as preoperative treatment in locally advanced esophageal cancer: A phase II study 47
Present and future of metastatic colorectal cancer treatment: A review of new candidate targets 47
Atypical haemolytic-uraemic syndrome in patient with metastatic colorectal cancer treated with fluorouracil and oxaliplatin: A case report and a review of literature 47
Liquid Biopsy at Home: Delivering Precision Medicine for Patients with Cancer During the Covid-19 Pandemic 47
MEK inhibitor as a single agent and in combination with everolimus or sorafenib in a panel of colorectal cancer cell lines: implication for multitargeted approach 46
Beyond bevacizumab: new anti-VEGF strategies in colorectal cancer. 46
PHASE I/II STUDY OF FOLFIRI PLUS THE MEK1/2 INHIBITOR PIMASERTIB (MSC1936369B) AS SECOND-LINE TREATMENT FOR KRAS MUTATED METASTATIC COLORECTAL CANCER 46
Type III or allosteric kinase inhibitors for the treatment of non-small cell lung cancer. 45
OPTIMIZING THERAPEUTIC COMBINATIONS OF A SELECTIVE MEK 1/2 INHIBITOR (PIMASERTIB) WITH PI3K/ MTOR INHIBITORS OR WITH MULTI-TARGETED KINASE INHIBITORS IN PIMASERTIB-RESISTANT HUMAN LUNG AND COLORECTAL CANCER CELLS 45
EGFR in Tumor-associated Myeloid Cells Promotes Development of Colorectal Cancer in Mice and Associates With Outcomes of Patients. 45
Efficacy of continuous EGFR-inhibition and role of Hedgehog in EGFR acquired resistance in human lung cancer cells with activating mutation of EGFR. 45
Dual inhibition of TGFβ and AXL as a novel therapy for human colorectal adenocarcinoma with mesenchymal phenotype 45
Anti-tumor activity of cetuximab plus avelumab in non-small cell lung cancer patients involves innate immunity activation: findings from the CAVE-Lung trial 45
Panitumumab: the evidence of its therapeutic potential in metastatic colorectal cancer 44
Metformin in lung cancer: rationale for a combination therapy 44
Synergistic effects of metformin treatment in combination with gefitinib, a selective EGFR tyrosine kinase inhibitor, in LKB1 wild-type NSCLC cell lines 44
SMO Gene Amplification and Activation of the Hedgehog Pathway as Novel Mechanisms of Resistance to Anti-Epidermal Growth Factor Receptor Drugs in Human Lung Cancer 44
Therapeutic value of EGFR inhibition in CRC and NSCLC: 15 years of clinical evidence. 44
Antitumor Efficacy of Dual Blockade of EGFR Signaling by Osimertinib in Combination With Selumetinib or Cetuximab in Activated EGFR Human NCLC Tumor Models 44
Systemic-inflammation-based score can predict prognosis in metastatic gastric cancer patients before first-line chemotherapy 44
Resistance mechanisms of tumour cells to EGFR inhibitors 43
Cetuximab continuation after first progression in metastatic colorectal cancer (CAPRI-GOIM): a randomized phase II trial of FOLFOX plus cetuximab versus FOLFOX. 43
Mechanisms of resistance to anti-epidermal growth factor receptor inhibitors in metastatic colorectal cancer 42
AXL is a predictor of poor survival and of resistance to anti-EGFR therapy in RAS wild-type metastatic colorectal cancer 42
Regorafenib for Patients with Metastatic Colorectal Cancer Who Progressed After Standard Therapy: Results of the Large, Single-Arm, Open-Label Phase IIIb CONSIGN Study 41
Sequence-dependent, synergistic antiproliferative and proapoptotic effects of the combination of cytotoxic drugs and enzastaurin, a protein kinase Cbeta inhibitor, in non-small cell lung cancer cells 41
Antitumor efficacy of triple monoclonal antibody inhibition of epidermal growth factor receptor (EGFR) with MM151 in EGFRdependent and in cetuximab-resistant human colorectal cancer cells 41
Genetic Landascape of Primary versus metastatic colorectal cancer: to what extent are they concordant ? 40
HER2 Positivity Predicts Unresponsiveness to EGFR-Targeted Treatment in Metastatic Colorectal Cancer 40
Gut microbiota correlates with antitumor activity in patients with mCRC and NSCLC treated with cetuximab plus avelumab 40
Receptor tyrosine kinase-dependent PI3K activation is an escape mechanism to vertical suppression of the EGFR/RAS/MAPK pathway in KRAS-mutated human colorectal cancer cell lines 39
Combination therapy with anti-EGFR monoclonal antibodies in the treatment of NSCLC. 38
Neutrophil to Lymphocyte Ratio as a Predictor of Poor Prognosis in Metastatic Pancreatic Cancer Patients Treated with Nab-Paclitaxel plus Gemcitabine: A Propensity Score Analysis 38
Cancer- and Non-cancer Related Chronic Pain: From the Physiopathological Basics to Management 38
The use of xenograft models for the selection of cancer treatments with the EGFR as an example 37
ROLE OF THE HEDGEHOG PATHWAY IN MEDIATING RESISTANCE TO ANTI-EGFR TYROSINE KINASE INHIBITORS IN NON SMALL CELL LUNG CANCER 37
Maintenance Treatment with Cetuximab and BAY86-9766 Increases Antitumor Efficacy of Irinotecan plus Cetuximab in Human Colorectal Cancer Xenograft Models 37
Phase I study of FOLFIRI plus pimasertib as second-line treatment for KRAS-mutated metastatic colorectal cancer 37
Heterogeneity of KRAS, NRAS, BRAF and PIK3CA mutations in metastatic colorectal cancer and potential effects on therapy in the CAPRI GOIM trial 37
Lack of efficacy of streptozocin and doxorubicin in patients with advanced pancreatic endocrine tumors. 37
Totale 5.404
Salva come PNG Salva come JPEG
Categoria #
all - tutte 34.596
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 34.596
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020731 0 118 38 23 102 22 145 73 86 69 42 13
2020/2021955 89 15 103 53 138 12 129 95 34 116 120 51
2021/20221.159 54 17 23 23 340 24 42 35 54 100 107 340
2022/20232.491 253 50 35 213 295 209 7 152 1.155 17 57 48
2023/20241.000 94 37 38 51 337 143 19 24 11 14 74 158
2024/2025146 57 89 0 0 0 0 0 0 0 0 0 0
Totale 7.586